The VENUS Clinical Study (Verifying the Effectiveness of the NUsurface® System) (VENUS)
Primary Purpose
Meniscectomy, Osteoarthritis
Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
NUsurface® Meniscus Implant
NSAID's and Non-surgical Treatment Options
Intra-Articular Injections with Corticosteroids
Intra-Articular Injections with Hyaluronic Acid (HA)
Sponsored by

About this trial
This is an interventional treatment trial for Meniscectomy focused on measuring NuSurface, Meniscus, Prosthesis, KOOS
Eligibility Criteria
Inclusion Criteria:
- Had > 6 months ago a medial partial meniscectomy as confirmed by patient history and MRI
- Has a KOOS Pain of ≤ 75 (100 being the highest attainable and no pain)
- Is between age 30 and 75 years (inclusive) at the time of study treatment
- Has neutral alignment ± 5º of the mechanical axis, i.e., the angle formed by a line drawn from the center of the femoral head to the medial tibial spine and a line drawn from the medial tibial spine to the center of the ankle joint
- Has ≥ 2 mm intact medial meniscal rim capable of being fitted with a NUsurface® device AND is also recommended for the baseline non-surgical (and, if likely to receive benefit, any injection) therapies to be administered in the study.
- Is willing to be entered into either arm of the study: implanted with the NUsurface device OR treated with the recommended control arm therapies.
- Is able to do the study required follow up visits, questionnaires, X-rays, and MRI's
- Is able and willing to understand and sign the study Informed Consent Form
- Is able to read and understand the national language of the country in which the relevant clinical site is located
Exclusion Criteria:
- Has a symptomatic knee because of a tear that could be addressed by a repeat partial meniscectomy leaving > 4 mm of medial meniscus rim
- Has evidence of a Outerbridge Grade IV cartilage loss on the medial tibial plateau or femoral condyle that potentially could contact a NUsurface implant (e.g., a focal lesion > 0.5 cm2 correlating to a circular defect of > 8 mm in diameter)
- Has complete disruption of the posterior root attachment of the meniscus
- Has lateral compartment pain and Grade III or Grade IV Outerbridge cartilage score in the lateral compartment
- Has a varus or valgus knee deformity > 5º requiring a tibial or femoral osteotomy
- Has a laxity level of more than Grade II (IKDC), primary or secondary to an injury of the anterior cruciate ligament (ACL) and/or posterior cruciate ligament (PCL) and/or lateral collateral ligament (LCL) and/or medial collateral ligament (MCL)
- Has significant trochlear dysplasia, patellar instability or symptomatic patellar misalignment
- Has patellar compartment pain and Grade III or Grade IV Outerbridge cartilage score in the patellar compartment.
- Compared to a normal knee, has obvious radiological evidence of medial femoral squaring, anatomical variance in the medial tibial plateau, or irregularly shaped cartilage surface
- Had an ACL reconstruction performed < 9 months prior to study treatment
- Has a BMI > 32.5 at the start of study treatment
- Decides to receive (if eligible and an option) allograft medial meniscus transplantation
- Received any type of prosthetic knee implant made of artificial non-resorbable plastic, metal or ceramic, not including the NUsurface® Meniscus Implant
- Has a knee flexion contracture > 10º
- Has flexion < 90º
- Had a previous medial femoral condyle surgery (not including microfracture) or High Tibial Osteotomy (HTO)
- Has insufficiency fractures or avascular necrosis of the medial compartment
- Has an active infection or tumor (local or systemic)
- Has any type of knee joint inflammatory disease including Sjogren's syndrome
- Has neuropathic knee osteoarthropathy, also known as Charcot joint
- Has any medical condition that does not allow possible arthroscopy of the knee
- Has neurological deficit (sensory, motor, or reflex)
- Is currently involved in another investigation of the lower extremity
- Anticipates having another lower extremity surgery during the study period
- Is contraindicated for hyaluronic acid injections (i.e., patients with known hypersensitivity [allergy] to hyaluronan [sodium hyaluoronate] preparations); patients having knee joint infections or skin diseases or infections in the site of possible injections
- Is contraindicated for corticosteroid injections (i.e., patients with allergy to any of the components or with idiopathic thrombocytopenic purpura)
- Has received any corticosteroid knee injections ≤ 3 months prior to study treatment
- Has chondrocalcinosis
- Is on immunostimulating or immunosuppressing agents
- Has ipsilateral or contralateral lower limb joint conditions that may affect ambulation or KOOS (e.g. have a leg length discrepancy > 2.5 cm [1 inch], causing a noticeable limp)
- Is a female who is lactating, expecting, or is intending to become pregnant during the study period
- Is an active smoker
- Is mentally incapacitated (incapable of appraising or controlling conduct) or have mental disability (e.g., dementia or Alzheimer's)
- Is a prisoner
- Is a patient who has economic incentive not to improve
Sites / Locations
- AZ Monica
- Centre Hospitalier de Versailles
- University Hospital of Munich
- Ichilov Hospital
- Assaf Harofeh Medical Center
- Ospedale Sacro Cuore - Don Calabria
- Academisch Ziekenhuis Maastricht
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Investigational arm
Control Arm
Arm Description
The patients randomized to the Investigational Group will receive the NUsurface® Meniscus Implant.
The patients randomized to the Control Group of the study will receive Non-Surgical Care (the current standard of care for this patient population).
Outcomes
Primary Outcome Measures
KOOS Scale
The KOOS Pain Subscale and KOOS Overall Scale (Average of the 5 KOOS Subscales) relative to baseline - all at 24 months.
NUsurface Device Related Complications
The device related complications of the NUsurface Meniscus Implant during the 24-month post-operative period in regard to secondary surgical intervention of the NUsurface device.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02136901
Brief Title
The VENUS Clinical Study (Verifying the Effectiveness of the NUsurface® System)
Acronym
VENUS
Official Title
The VENUS Clinical Study (Verifying the Effectiveness of the NUsurface® System) A Multi-center, Prospective, Randomized, Interventional, Superiority Clinical Study
Study Type
Interventional
2. Study Status
Record Verification Date
July 2020
Overall Recruitment Status
Completed
Study Start Date
June 2014 (Actual)
Primary Completion Date
June 2020 (Actual)
Study Completion Date
June 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Active Implants
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The NUsurface® Meniscus Implant Randomized Study is a multi-center, prospective randomized, interventional clinical trial to test the hypothesis that the NUsurface implant is superior to the non-surgical standard of care in treating the target population.The rationale for performing this clinical study is to gather clinical data to evaluate the safety and effectiveness of the NUsurface device compared to the Standard of Care.
Detailed Description
The NUsurface® Meniscus Implant is intended for use in patients with medial compartment pain that have had a previous partial medial meniscectomy.
Patients who meet the inclusion/exclusion criteria will be assigned by balanced randomization into one of two groups: the Meniscus Implants versus non-surgical standard of care. The KOOS (Knee injury and Osteoarthritis Outcome Score) and IKDC (International Knee Documentation Committee) forms will be used to provide a comprehensive evaluation of the patients' pre-intervention and post-intervention condition including activity levels, pain, swelling, locking, stability, support, sports activity, and quality of life assessment.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Meniscectomy, Osteoarthritis
Keywords
NuSurface, Meniscus, Prosthesis, KOOS
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
34 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Investigational arm
Arm Type
Experimental
Arm Description
The patients randomized to the Investigational Group will receive the NUsurface® Meniscus Implant.
Arm Title
Control Arm
Arm Type
Active Comparator
Arm Description
The patients randomized to the Control Group of the study will receive Non-Surgical Care (the current standard of care for this patient population).
Intervention Type
Device
Intervention Name(s)
NUsurface® Meniscus Implant
Intervention Description
The NUsurface Meniscus Implant is a Polycarbonate-Urethane (PCU)-based device reinforced with high tensile Ultra High Molecular Weight Polyethylene (UHMWPE) fibers. The product is available in different sizes, left and right, and with trials so as to allow the surgeon several size options for implantation. The NUsurface® Meniscus Implant, is designed to be conceptually analogous to the natural meniscus whose structural characteristics include a highly orientated collagen fiber network supports the large hoop stresses to produce better distribution of contact pressures within the knee joint. Restoring the distribution of joint loads post-meniscectomy is thought to reducing joint overload and to reducing pain.
Intervention Type
Drug
Intervention Name(s)
NSAID's and Non-surgical Treatment Options
Intervention Description
Non-prescription drugs, creams, vitamins, and supplements, Prescription or Non-Prescriptions NSAIDs, Non-weight bearing and/or open chain physical therapy or self-administered exercise
Intervention Type
Drug
Intervention Name(s)
Intra-Articular Injections with Corticosteroids
Intervention Description
Intra-articular injection of a corticosteroid, such as 40 mg of Triamcinolone (e.g. Aristocort or Kenalog).
Intervention Type
Drug
Intervention Name(s)
Intra-Articular Injections with Hyaluronic Acid (HA)
Intervention Description
Intra-articular injection of a hyaluronic acid treatment, such as SYNVISC® HA Injections.
Primary Outcome Measure Information:
Title
KOOS Scale
Description
The KOOS Pain Subscale and KOOS Overall Scale (Average of the 5 KOOS Subscales) relative to baseline - all at 24 months.
Time Frame
2 years
Title
NUsurface Device Related Complications
Description
The device related complications of the NUsurface Meniscus Implant during the 24-month post-operative period in regard to secondary surgical intervention of the NUsurface device.
Time Frame
2 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Had > 6 months ago a medial partial meniscectomy as confirmed by patient history and MRI
Has a KOOS Pain of ≤ 75 (100 being the highest attainable and no pain)
Is between age 30 and 75 years (inclusive) at the time of study treatment
Has neutral alignment ± 5º of the mechanical axis, i.e., the angle formed by a line drawn from the center of the femoral head to the medial tibial spine and a line drawn from the medial tibial spine to the center of the ankle joint
Has ≥ 2 mm intact medial meniscal rim capable of being fitted with a NUsurface® device AND is also recommended for the baseline non-surgical (and, if likely to receive benefit, any injection) therapies to be administered in the study.
Is willing to be entered into either arm of the study: implanted with the NUsurface device OR treated with the recommended control arm therapies.
Is able to do the study required follow up visits, questionnaires, X-rays, and MRI's
Is able and willing to understand and sign the study Informed Consent Form
Is able to read and understand the national language of the country in which the relevant clinical site is located
Exclusion Criteria:
Has a symptomatic knee because of a tear that could be addressed by a repeat partial meniscectomy leaving > 4 mm of medial meniscus rim
Has evidence of a Outerbridge Grade IV cartilage loss on the medial tibial plateau or femoral condyle that potentially could contact a NUsurface implant (e.g., a focal lesion > 0.5 cm2 correlating to a circular defect of > 8 mm in diameter)
Has complete disruption of the posterior root attachment of the meniscus
Has lateral compartment pain and Grade III or Grade IV Outerbridge cartilage score in the lateral compartment
Has a varus or valgus knee deformity > 5º requiring a tibial or femoral osteotomy
Has a laxity level of more than Grade II (IKDC), primary or secondary to an injury of the anterior cruciate ligament (ACL) and/or posterior cruciate ligament (PCL) and/or lateral collateral ligament (LCL) and/or medial collateral ligament (MCL)
Has significant trochlear dysplasia, patellar instability or symptomatic patellar misalignment
Has patellar compartment pain and Grade III or Grade IV Outerbridge cartilage score in the patellar compartment.
Compared to a normal knee, has obvious radiological evidence of medial femoral squaring, anatomical variance in the medial tibial plateau, or irregularly shaped cartilage surface
Had an ACL reconstruction performed < 9 months prior to study treatment
Has a BMI > 32.5 at the start of study treatment
Decides to receive (if eligible and an option) allograft medial meniscus transplantation
Received any type of prosthetic knee implant made of artificial non-resorbable plastic, metal or ceramic, not including the NUsurface® Meniscus Implant
Has a knee flexion contracture > 10º
Has flexion < 90º
Had a previous medial femoral condyle surgery (not including microfracture) or High Tibial Osteotomy (HTO)
Has insufficiency fractures or avascular necrosis of the medial compartment
Has an active infection or tumor (local or systemic)
Has any type of knee joint inflammatory disease including Sjogren's syndrome
Has neuropathic knee osteoarthropathy, also known as Charcot joint
Has any medical condition that does not allow possible arthroscopy of the knee
Has neurological deficit (sensory, motor, or reflex)
Is currently involved in another investigation of the lower extremity
Anticipates having another lower extremity surgery during the study period
Is contraindicated for hyaluronic acid injections (i.e., patients with known hypersensitivity [allergy] to hyaluronan [sodium hyaluoronate] preparations); patients having knee joint infections or skin diseases or infections in the site of possible injections
Is contraindicated for corticosteroid injections (i.e., patients with allergy to any of the components or with idiopathic thrombocytopenic purpura)
Has received any corticosteroid knee injections ≤ 3 months prior to study treatment
Has chondrocalcinosis
Is on immunostimulating or immunosuppressing agents
Has ipsilateral or contralateral lower limb joint conditions that may affect ambulation or KOOS (e.g. have a leg length discrepancy > 2.5 cm [1 inch], causing a noticeable limp)
Is a female who is lactating, expecting, or is intending to become pregnant during the study period
Is an active smoker
Is mentally incapacitated (incapable of appraising or controlling conduct) or have mental disability (e.g., dementia or Alzheimer's)
Is a prisoner
Is a patient who has economic incentive not to improve
Facility Information:
Facility Name
AZ Monica
City
Antwerp
ZIP/Postal Code
BE-2018
Country
Belgium
Facility Name
Centre Hospitalier de Versailles
City
Le Chesnay CEDEX
ZIP/Postal Code
F 78158
Country
France
Facility Name
University Hospital of Munich
City
Munich
ZIP/Postal Code
81377
Country
Germany
Facility Name
Ichilov Hospital
City
Tel Aviv
ZIP/Postal Code
64239
Country
Israel
Facility Name
Assaf Harofeh Medical Center
City
Zerifin
ZIP/Postal Code
70300
Country
Israel
Facility Name
Ospedale Sacro Cuore - Don Calabria
City
Negrar
State/Province
Verona
ZIP/Postal Code
37024
Country
Italy
Facility Name
Academisch Ziekenhuis Maastricht
City
Maastricht
ZIP/Postal Code
66202
Country
Netherlands
12. IPD Sharing Statement
Citations:
PubMed Identifier
24055793
Citation
Shemesh M, Asher R, Zylberberg E, Guilak F, Linder-Ganz E, Elsner JJ. Viscoelastic properties of a synthetic meniscus implant. J Mech Behav Biomed Mater. 2014 Jan;29:42-55. doi: 10.1016/j.jmbbm.2013.08.021. Epub 2013 Sep 3.
Results Reference
background
PubMed Identifier
20635076
Citation
Zur G, Linder-Ganz E, Elsner JJ, Shani J, Brenner O, Agar G, Hershman EB, Arnoczky SP, Guilak F, Shterling A. Chondroprotective effects of a polycarbonate-urethane meniscal implant: histopathological results in a sheep model. Knee Surg Sports Traumatol Arthrosc. 2011 Feb;19(2):255-63. doi: 10.1007/s00167-010-1210-5. Epub 2010 Jul 16.
Results Reference
background
PubMed Identifier
20887018
Citation
Elsner JJ, Portnoy S, Guilak F, Shterling A, Linder-Ganz E. MRI-based characterization of bone anatomy in the human knee for size matching of a medial meniscal implant. J Biomech Eng. 2010 Oct;132(10):101008. doi: 10.1115/1.4002490.
Results Reference
background
PubMed Identifier
20815651
Citation
Elsner JJ, Portnoy S, Zur G, Guilak F, Shterling A, Linder-Ganz E. Design of a free-floating polycarbonate-urethane meniscal implant using finite element modeling and experimental validation. J Biomech Eng. 2010 Sep;132(9):095001. doi: 10.1115/1.4001892.
Results Reference
background
PubMed Identifier
20370247
Citation
Linder-Ganz E, Elsner JJ, Danino A, Guilak F, Shterling A. A novel quantitative approach for evaluating contact mechanics of meniscal replacements. J Biomech Eng. 2010 Feb;132(2):024501. doi: 10.1115/1.4000407.
Results Reference
background
PubMed Identifier
26057364
Citation
Elsner JJ, Shemesh M, Shefy-Peleg A, Gabet Y, Zylberberg E, Linder-Ganz E. Quantification of in vitro wear of a synthetic meniscus implant using gravimetric and micro-CT measurements. J Mech Behav Biomed Mater. 2015 Sep;49:310-20. doi: 10.1016/j.jmbbm.2015.05.017. Epub 2015 May 28.
Results Reference
background
PubMed Identifier
25238685
Citation
De Coninck T, Elsner JJ, Linder-Ganz E, Cromheecke M, Shemesh M, Huysse W, Verdonk R, Verstraete K, Verdonk P. In-vivo evaluation of the kinematic behavior of an artificial medial meniscus implant: A pilot study using open-MRI. Clin Biomech (Bristol, Avon). 2014 Sep;29(8):898-905. doi: 10.1016/j.clinbiomech.2014.07.001. Epub 2014 Jul 17.
Results Reference
result
Learn more about this trial
The VENUS Clinical Study (Verifying the Effectiveness of the NUsurface® System)
We'll reach out to this number within 24 hrs